Eyal Rubin - 23 Sep 2024 Form 4/A - Amendment Insider Report for Protalix BioTherapeutics, Inc. (PLX)

Role
Sr. VP and CFO
Signature
/s/ Eyal Rubin
Issuer symbol
PLX
Transactions as of
23 Sep 2024
Net transactions value
$0
Form type
4/A - Amendment
Filing time
05 Nov 2024, 17:00:15 UTC
Date Of Original Report
24 Sep 2024
Previous filing
17 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLX Common Stock Award +90,909 +16% 660,909 23 Sep 2024 By Trust F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The original Form 4, filed on September 24, 2024, is being amended by this Form 4 amendment solely to correct an administrative error, which misreported the amount of restricted shares granted.
F2 Represents fully-vested restricted shares of common stock of Protalix BioTherapeutics, Inc., awarded to the Reporting Person under the Amended and Restated Protalix BioTherapeutics, Inc. 2006 Stock Incentive Plan, as amended.
F3 To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Plan must be registered in the name of a trustee.